Erasca, Inc.
NASDAQ:ERASBiotechnology
Healthcare
$13.76 -0.14%
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
52W Low $1.21High $24.28
Volume 8.94M
Average 6.79M
Balance Sheet
Inspect the capital base behind the business.
Assets
$396.15M
FY 2025 · Annual
-21.2% YoYLiabilities
$70.98M
FY 2025 · Annual
-10.2% YoYEquity
$325.17M
FY 2025 · Annual
-23.2% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 360.49M | 284.22M | 93.08M | 67.74M | 73.81M |
| Short-term Investments | 53.99M | 151.4M | 219.28M | 230.57M | 202.27M |
| Net Receivables | 0 | 0 | 0 | 2.3M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 100K | 748K | 1.1M | 8.18M | 7.66M |
| Total Current Assets | 420.02M | 444.5M | 320.68M | 308.79M | 286.24M |
| Property, Plant & Equipment (Net) | 33.31M | 65.23M | 60.19M | 48.54M | 42.33M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 44.77M | 2M | 10.05M | 142.16M | 66.13M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.32M | 3.18M | 4.38M | 3.03M | 1.45M |
| Total Non-current Assets | 81.4M | 70.41M | 74.62M | 193.73M | 109.92M |
| Total Assets | 501.42M | 514.91M | 395.3M | 502.53M | 396.15M |
| Account Payables | 4.68M | 23.05M | 2M | 468K | 981K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.16M | 2.33M | 10.78M | 10.65M | 12.07M |
| Total Current Liabilities | 26.22M | 48.69M | 26.16M | 31.4M | 28.51M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 158K | 573K | 566K | 362K | 399K |
| Total Non-current Liabilities | 18.66M | 54.37M | 52.46M | 47.63M | 42.47M |
| Total Liabilities | 44.89M | 103.06M | 78.61M | 79.03M | 70.98M |
| Common Stock | 12K | 15K | 15K | 28K | 28K |
| Retained Earnings | (238.17M) | (480.97M) | (606.01M) | (767.66M) | (892.21M) |
| Accumulated OCI | (162K) | (1.04M) | 77K | 405K | 628K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 456.53M | 411.85M | 316.69M | 423.5M | 325.17M |
| Total Debt | 18.79M | 55.1M | 55.86M | 51.89M | 47.14M |
| Net Debt | (341.7M) | (229.12M) | (37.22M) | (15.85M) | (26.67M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $119.0M |
| Short-term Investments | $524.7M |
| Other Current | $11.5M |
| Total Current Assets | $655.2M |
| PP&E (Net) | $38.0M |
| Long-term Investments | $304.1M |
| Other Non-current | $1.6M |
| Total Non-current Assets | $343.7M |
| Total Assets | $998.9M |
Analysis
Selected assets total $998.9M for Latest. The largest visible component is Short-term Investments at $524.7M, about 52.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Oct 16, 2026 | |
| 8-K | Current report | Aug 24, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much cash does ERAS have?
Erasca, Inc. (ERAS) reported $73.81M in cash and equivalents in fiscal 2025.
How much debt does ERAS carry?
Erasca, Inc. (ERAS) reported $47.14M of total debt, with net debt of -$26.67M.
Continue the stock analysis
Jump to another research area for this company.